Eversept Partners’s ARK Genomic Revolution ETF ARKG Stock Holding History
Bought
Maintained
Sold
Other funds holding ARKG
APM
Eversept Partners's ARKG Position: Q2 2022 in Review
Eversept Partners sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2022, closing a stake of 470,506 shares — an estimated $21.6M sold.
Eversept Partners first reported a position in ARKG in Q1 2021 and held it in 5 quarters. The position peaked at $71.6M in Q1 2021. 333 funds tracked by Wall St. Rank hold ARKG as of Q2 2022.
- Eversept Partners reported no remaining ARK Genomic Revolution ETF position as of Q2 2022 after selling out during the quarter.
- Eversept Partners sold 470,506 ARK Genomic Revolution ETF shares in Q2 2022, an estimated $21.6M.
- Eversept Partners first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 5 quarters.
- Eversept Partners's ARK Genomic Revolution ETF position peaked at $71.6M in Q1 2021.
- 333 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2022.
Based on Eversept Partners's 13F filing for Q2 2022, filed 15 Aug 2022.